When Should Lymphadenectomy Be Performed in Non-Metastatic Pancreatic Neuroendocrine Tumors? A Population-Based Analysis of the German Clinical Cancer Registry Group

• Published in: Cancers 2024-01, Vol.16 (2), p.440
• Main Authors: Abdalla, Thaer S A, Bolm, Louisa, Klinkhammer-Schalke, Monika, Zeissig, Sylke Ruth, Kleihues van Tol, Kees, Bronsert, Peter, Litkevych, Stanislav, Honselmann, Kim C, Braun, Rüdiger, Gebauer, Judith, Hummel, Richard, Keck, Tobias, Wellner, Ulrich Friedrich, Deichmann, Steffen
• Format: Article
• Language: English
• Subjects: Cancer; Decision making; Health aspects; Lymph nodes; Lymphatic system; Medical prognosis; Metastases; Metastasis; Neuroendocrine tumors; Pancreas; Parenchyma; Patients; Population studies; Prediction models; Survival; Variables
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16020440

Patient selection for lymphadenectomy remains a controversial aspect in the treatment of pancreatic neuroendocrine tumors (pNETs), given the growing importance of parenchyma-sparing resections and minimally invasive procedures. This population-based analysis was derived from the German Cancer Registry Group during the period from 2000 to 2021. Patients with upfront resected non-functional non-metastatic pNETs were included. Out of 5520 patients with pNET, 1006 patients met the inclusion criteria. Fifty-three percent of the patients were male. The median age was 64 ± 17 years. G1, G2, and G3 pNETs were found in 57%, 37%, and 7% of the patients, respectively. Lymph node metastasis (LNM) was present in 253 (24%) of all patients. LNM was an independent prognostic factor (HR 1.79, CI 95% 1.21-2.64, = 0.001) for disease-free survival (DFS). The 3-, 5-, and 10-year disease-free survival in nodal negative tumors compared to nodal positive was 82% vs. 53%, 75% vs. 38%, and 48% vs. 16%. LNM was present in 5% of T1 tumors, 25% of T2 tumors, and 49% of T3-T4 tumors. In T1 tumors, G1 was the most predominant tumor grade (80%). However, in T2 tumors, G2 and G3 represented 44% and 5% of all tumors. LNM was associated with tumors located in the pancreatic head ( < 0.001), positive resection margin ( < 0.001), tumors larger than 2 cm ( < 0.001), and higher tumor grade ( < 0.001). The multivariable analysis showed that tumor size, tumor grade, and location were independent prognostic factors associated with LNM that could potentially be used to predict LNM preoperatively. LNM is an independent negative prognostic factor for DFS in pNETs. Due to the low incidence of LNM in T1 tumors (5%), parenchyma-sparing surgery seems oncologically adequate in small G1 pNETs, while regional lymphadenectomy should be recommended in T2 or G2/G3 pNETs.